MTOR and neoplasm: Interestingly, immunosuppression is correlated with tumor occurrence risk (15), some HCC pathways are also the target of some immunosuppression agents, such as the mammalian target of rapamycin (mTOR) inhibitors (mTORi) (16, 17) (Figure 1).